![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00478049 |
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational sites throughout the Asia Pacific region that have expertise in treating patients with NSCLC.
Condition | Intervention | Phase |
---|---|---|
NSCLC |
Drug: Gefitinib Drug: Docetaxel |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA) |
Enrollment: | 163 |
Study Start Date: | September 2005 |
Study Completion Date: | February 2009 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Docetaxel
|
Drug: Docetaxel
intravenous infusion
|
2: Experimental
Gefitinib
|
Drug: Gefitinib
250 mg oral tablet
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |
Research Site | |
In Cheon, Korea, Republic of | |
Research Site | |
Kyonggi-do, Korea, Republic of | |
Research Site | |
Seoul, Korea, Republic of | |
Research Site | |
Suwon, Korea, Republic of |
Principal Investigator: | SangWe Kim, MD | Asan Medical Center |
Study ID Numbers: | D7913L00039 |
Study First Received: | May 23, 2007 |
Last Updated: | April 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00478049 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Non-Small Cell Lung Cancer |
Docetaxel Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases Non-small Cell Lung Cancer |
Protein Kinase Inhibitors Gefitinib Carcinoma, Non-Small-Cell Lung Recurrence Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Carcinoma Docetaxel |
Neoplasms Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Lung Diseases Carcinoma, Non-Small-Cell Lung Gefitinib Neoplasms, Glandular and Epithelial |